Ribo revela datos positivos del ensayo de fase 2a de vortosiran

Phase 2positivevortosiranPositive

AI Analysis

Summary

Ribo announced positive Phase 2a trial data for vortosiran, an siRNA-based FXI inhibitor, in patients with coronary artery disease. The data represent the first clinical evidence of FXI inhibition via siRNA following multiple dose administration.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

First global clinical data on FXI inhibition mediated by siRNA following multiple dose administration in patients with coronary artery disease

Importance:6/10

Sentiment:

0.75

Phase 2 datasiRNAFXI inhibitioncoronary artery diseasepositive results

Read the original article

Published by PR Newswire Biotech on July 22, 2026 2:11 PM

Read Original